ARS Pharmaceuticals Inc
SPRY16.870USD
-0.580-3.32%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.66BCap. mercado
206.98P/E TTM
Más Datos de ARS Pharmaceuticals Inc Compañía
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Información de la empresa
Símbolo de cotizaciónSPRY
Nombre de la empresaARS Pharmaceuticals Inc
Fecha de salida a bolsaDec 04, 2020
Fundada en2016
Director ejecutivoMr. Richard E. Lowenthal
Número de empleados155
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 04
Dirección11682 El Camino Real, Suite 120
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92130
Teléfono18587719307
Sitio Webhttps://ars-pharma.com/
Símbolo de cotizaciónSPRY
Fecha de salida a bolsaDec 04, 2020
Fundada en2016
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Justin Chakma
Mr. Justin Chakma
Chief Business Officer
Chief Business Officer
136.38K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Rajeev Dadoo, Ph.D.
Dr. Rajeev Dadoo, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Justin Chakma
Mr. Justin Chakma
Chief Business Officer
Chief Business Officer
136.38K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: lun., 2 de jun
Actualizado: lun., 2 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
11.06%
Deerfield Management Company, L.P.
10.71%
OrbiMed Advisors, LLC
8.44%
Lowenthal (Richard E)
6.95%
Pratik Shah Living Trust
4.91%
Other
57.93%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
11.06%
Deerfield Management Company, L.P.
10.71%
OrbiMed Advisors, LLC
8.44%
Lowenthal (Richard E)
6.95%
Pratik Shah Living Trust
4.91%
Other
57.93%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
20.71%
Hedge Fund
19.64%
Venture Capital
15.20%
Investment Advisor
13.88%
Individual Investor
12.16%
Private Equity
8.44%
Corporation
4.91%
Research Firm
2.18%
Pension Fund
0.27%
Other
2.62%
Participación institucional
Actualizado: hace 11 horas
Actualizado: hace 11 horas
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
361
95.98M
97.72%
-8.84M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
2023Q3
283
95.82M
104.35%
+1.21M
2023Q2
278
88.26M
96.94%
-730.20K
2023Q1
271
88.79M
98.08%
+1.91M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
10.86M
11.06%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
10.51M
10.71%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
8.29M
8.44%
--
--
Mar 31, 2025
Lowenthal (Richard E)
6.83M
6.95%
-1.14M
-14.34%
Mar 31, 2025
Pratik Shah Living Trust
4.82M
4.91%
--
--
Mar 31, 2025
Tanimoto (Sarina)
4.57M
4.66%
-556.66K
-10.85%
Mar 31, 2025
SR One Capital Management, LP
4.01M
4.09%
--
--
Mar 31, 2025
AllianceBernstein L.P.
3.92M
3.99%
+42.07K
+1.08%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.88M
3.95%
-275.85K
-6.63%
Mar 31, 2025
The Vanguard Group, Inc.
3.48M
3.54%
+23.34K
+0.68%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
First Trust Small Cap Growth AlphaDEX Fund
0.6%
Janus Henderson Small Cap Growth Alpha ETF
0.39%
First Trust Small Cap Core Alphadex Fund
0.29%
SPDR S&P Biotech ETF
0.24%
iShares Micro-Cap ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
First Trust Multicap Growth Alphadex Fund
0.11%
Principal U.S. Small-Cap ETF
0.11%
Ver más
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.6%
Janus Henderson Small Cap Growth Alpha ETF
Proporción0.39%
First Trust Small Cap Core Alphadex Fund
Proporción0.29%
SPDR S&P Biotech ETF
Proporción0.24%
iShares Micro-Cap ETF
Proporción0.16%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.16%
ProShares Ultra Nasdaq Biotechnology
Proporción0.14%
Invesco Nasdaq Biotechnology ETF
Proporción0.14%
First Trust Multicap Growth Alphadex Fund
Proporción0.11%
Principal U.S. Small-Cap ETF
Proporción0.11%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
